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• People with Lynch syndrome are at an increased risk of a range of cancers.
• This is the first systematic review of test accuracy of testing for Lynch syndrome in women with endomentrial cancer.
• The sensitivity of the index tests were generally high, though most studies had much lower specificity.
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MLH1 promoter methylation testingBackground. Lynch syndrome is an inherited genetic condition that is associatedwith an increased risk of can-
cer, including endometrial and colorectal cancer. We assessed the test accuracy of immunohistochemistry and
microsatellite instability-based testing (with or without MLH1 promoter methylation testing) for Lynch syn-
drome in women with endometrial cancer.
Methods. We conducted a systematic review of literature published up to August 2019. We searched biblio-
graphic databases, contacted experts and checked reference lists of relevant studies. Two reviewers conducted
each stage of the review.
Results. Thirteen studies were identified that included approximately 3500 participants. None of the studies
was at low risk of bias in all domains. Data could not be pooled due to the small number of heterogeneous studies.
Sensitivity ranged from 60.7–100% for immunohistochemistry, 41.7–100% for microsatellite instability-based
testing, and 90.5–100% for studies combining immunohistochemistry, microsatellite instability-based testing,
and MLH1 promoter methylation testing. Specificity ranged from 60.9–83.3% (excluding 1 study with highly se-
lective inclusion criteria) for immunohistochemistry, 69.2–89.9% for microsatellite instability-based testing, and
72.4–92.3% (excluding 1 study with highly selective inclusion criteria) for testing strategies that included immu-
nohistochemistry, microsatellite instability-based testing, andMLH1 promoter methylation.We found no statis-
tically significant differences in test accuracy estimates (sensitivity, specificity) in head-to-head studies of
immunohistochemistry versus microsatellite instability-based testing. Reported test failures were rare.
Conclusions. Sensitivity of the index tests were generally high, thoughmost studies hadmuch lower specific-
ity.We found no evidence that test accuracy differed between IHC andMSI based strategies. The evidence base is
currently small and at high risk of bias.
© 2020 Published by Elsevier Inc.ibonucleic acid; FN, False negative; FP, False positive; IHC, Immunohistochemistry; IQR, Interquartile range; MHL1, MutL
; MSH2, MutS homologue 2; MSH6, MutS homologue 6; MSI, Microsatellite instability-based testing; MMR, Mismatch repair;
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gnostic Accuracy Studies 2; TN, True negative; TP, True positive.
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Endometrial cancer is the most common gynaecological cancer in
the Western world [1]. The incidence of endometrial cancer generally
increases with age, reaching a peak of 97.3 per 100,000 population be-
tween the ages of 75 and 79 years [2]. A recent estimate suggests that
people with endometrial cancer have a 1-year survival rate of 89.6%
and a 5-year survival rate of 75.7% [3]. Risk factors for the development
of endometrial cancer include obesity, nulliparity, early age at menar-
che, use of hormone-replacement therapy, and gene mutations (e.g.
Lynch syndrome) [4–6].
Lynch syndrome is an autosomal dominant cancer-predisposition
syndrome that is most frequently caused by mutations to any of four
mismatch repair (MMR) genes: MutL homologue 1 (MLH1), MutS ho-
mologue 2 (MSH2), MutS homologue 6 (MSH6), or postmeiotic segre-
gation increased 2 (PMS2) [7]. MMR genes encode proteins that are
involved in recognising and repairing errors that occur in DNA during
cell division. Mutations in MMR genes prevent DNA errors from being
corrected, which can result in uncontrolled cell growth and the devel-
opment of cancer. The most common cancers among people with
Lynch syndrome are colorectal and endometrial cancers [8]. Detection
of Lynch syndrome might lead to reductions in the risk of developing
cancer for both the individual and their family members (through2
surveillance and risk-reducing strategies such as chemoprevention)
and earlier treatment of cancers. Two main tests are used to identify
peoplewho are at higher risk of Lynch syndrome: immunohistochemis-
try (IHC) and microsatellite instability (MSI)-based testing. Additional
testing for MLH1 promoter hypermethylation can assist in the identifi-
cation of sporadic cancers. Universal testing for Lynch syndrome in peo-
ple with endometrial cancer has been recommended by professional
organisations in the Europe and the US. [9,10] The present review was
commission by NICE in the UK to determinewhether to conduct testing
there.
A recent systematic reviewof IHC andMSI for Lynch syndrome in co-
lorectal cancer has suggested sensitivity and specificity are variable for
each of the tests [11]. No such systematic assessment has been con-
ducted in endometrial cancer. The aim of this systematic review is to as-
sess the test accuracy and test failure rates of IHC and MSI-based
strategies for detecting Lynch syndrome in peoplewho have a diagnosis
of endometrial cancer.2. Methods
The review is registered on the PROSPERO database (registration
number CRD42019147185) and the protocol is available from the NICE
website (www.nice.org.uk/guidance/indevelopment/gid-dg10033).
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The search strategy comprised the following main elements:
1) Searching of electronic bibliographic databases,
2) Contacting experts in the field, and
3) Scrutiny of references of included studies and relevant systematic
reviews.
Searches were developed iteratively and conducted in the following
databases, from inception: MEDLINE (Ovid); Embase (Ovid); Cochrane
Database of Systematic Reviews and Cochrane Central Register of Con-
trolled Trial (Wiley); Database of Abstracts of Reviews of Effects and
Health Technology Assessment database (CRD), Science Citation Index
and Conference Proceedings (Web of Science), and PROSPERO Interna-
tional Prospective Register of Systematic Reviews (CRD). Search terms
related to endometrial cancer and Lynch syndrome. Full details of the
search strategies are provided in Supplement 1. Searches were under-
taken in August 2019.
2.2. Eligibility criteria
We included English language journal articles that investigated test-
ing for Lynch syndrome by immunohistochemistry or microsatellite
instability-based testing (with orwithoutMLH1 promoter hypermethy-
lation testing) in women who have endometrial cancer. The primary
reference standardwas genetic verifications of constitutional mutations
in the MMR genes by sequencing/next-generation sequencing (with or
without multiplex ligation-dependent probe amplification). Other ac-
ceptable reference standards were array-based comparative genomic
hybridization, and long-range polymerase chain reaction. Outcomes
were any reported test accuracy measure, or test failures. We excludedFig. 1. PRISMA fl
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studies ofwomenwith pre-cancerous conditions of the uterus (i.e. atyp-
ical endometrial hyperplasia), articles not available in English, non-
human studies, letters, reviews, editorials, grey literature, conference
abstracts, and communications. We also excluded studies without ex-
tractable numerical data or with insufficient information for quality ap-
praisal, studies where more than 10% of the sample do not meet our
inclusion criteria, and studies in which fewer than 95% of women who
had the index test (or who were index test positive for studies with in-
complete test accuracy results) had germline testing (to minimise sam-
pling biases).2.3. Screening and data extraction
Two reviewers independently screened titles, abstracts, full text pa-
pers, and extracted data. At each stage of the review, disagreements
were resolved through discussion between the reviewers, with the in-
volvement of a third reviewer if required.2.4. Quality appraisal
Quality appraisal was assessed independently by two reviewers
using the Quality Assessment Tool for Diagnostic Accuracy Studies
(QUADAS-2) [12]. We tailored the tool to the research question. Tailor-
ing comprised (1) adding a domain to assess whether quality assurance
measures were in place, (2) defining inappropriate participant exclu-
sion criteria, (3) identifying appropriate reference standards, and
(4) adding a domain on the role of the sponsors.We also produced guid-
ance notes. Disagreements were resolved through discussion between
the two reviewers, with the involvement of a third reviewer if required.ow diagram.
Fig. 2. Risk of bias in complete test accuracy studies.
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2.5. Data summary and synthesis
In an ideal test accuracy study, an entire sample of participants re-
ceives both the index test and the reference standard. This facilitates di-
rect comparisons of the agreement between the two tests, and
minimises biases thatmight occur as result of participant characteristics
differing at each stage of the process. For reasons of costs, practicality,
and ethics, in some test accuracy studies only a subset of participants re-
ceive both tests, i.e. only those who are index test positive will be of-
fered the reference standard; participants who are index test negative
receive no further testing. This approach accurately reflects how tests
are used in clinical practice, but can lead to inaccurate estimates of
test accuracy as the true diagnostic status of participants who are
index test negative is not known. This ‘partial verification bias’ has
been found to overestimate sensitivity and underestimate specificity
[13]. In this paper, we divide results in complete test accuracy studies
(in which participants have received both the index test and reference
standard) and partial test accuracy studies (in which only participants
who are index test negative receive the reference standard). For com-
plete test accuracy studies, we extracted data on true positives, false
positives, false negatives, and true negatives and calculated sensitivity,
specificity, positive predictive value (PPV), and negative predictive
value (NPV). For partial test accuracy studies (inwhich sensitivity, spec-
ificity, andNPV could not be calculated),we extracted true positives and
false positives, and calculated PPV. Confidence intervals were calculated
using Wilson's continuity correction [14].Fig. 3. Risk of bias in partia
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Meta-analysis of test accuracy was not possible due to the small
number of heterogeneous studies. We provide a narrative summary of
results, reporting test accuracy estimates and presenting forest plots.
Summary statistics and forest plots were generated using Stata 16 [15].
3. Results
3.1. Searching, sifting, and sorting
Fig. 1 provides full details of the flow of studies through the review.
We identified 3308 unique records through electronic databases. One
additional study was provided after contact with experts [16]. After ex-
amination of titles and abstracts, 326 papers were retained for full text
assessment. Thirteen papers met the review's inclusion criteria and
were included in the review (7 complete test accuracy, 6 partial test ac-
curacy). Supplement 4 contains a list of excluded studies (with reasons
for exclusions).
3.2. Quality appraisal
Figs. 2 and 3 provide summaries of risks of bias of the included stud-
ies. Quality appraisal for each individual study is shown in Supplement 5.
3.2.1. Complete test accuracy
Risk of bias was high in two or more domains for six studies (85.7%)
[17–22]. The remaining studywas at unclear risk of bias infive domains,
and low risk of bias in two domains [23]. No studywas at low risk of bias
in all domains. In the patient selection domain, there was a high risk of
bias in 85.7% of studies (6/7 studies) [17–22]. In the index test domain,l test accuracy studies.
Table 1
Characteristics of included studies.
Study
reference
Country Study design Study setting Time
period
Sample
size
included
Selected/
unselected
sample
Age Mean
Median (range
Ethnicity Previous /concurrent
cancers
Relatives Index test(s) Reference standard
tests(s)
Berends
2003
Netherlands Retrospective
and
prospective
cohort
Cancer registry Before
1989–2000
58 Selected Median 45
(27–49) years
NR 13/38 (22.4%) 22/58 (37.9%) cancer
diagnosis in 1st degree
relatives
MSI and IHC DGGE and
sequencing
Chao 2019 China Prospective
cohort
Hospital Dec
2017-Aug
2018
111 Selected Mean
55.7 years
NR 0 – excluded 14/111 (12.6%)
Amsterdam II criteria,
2 met Bethesda
criteria
IHC, MSI and MLH1
promoter
hypermethylation
testing
NGS and Sanger
sequencing
Median 55
(31–82) years
Goodfellow
2015
USA Propsective
cohort
Hospital 2003–2007 1043 Selected
after 2007
Mean 62
(25–100)
years
White, n = 848
(90.4%)
NR 938/1043 (90%) had
Lynch associated
cancers
MSI, IHC and MLH1
promoter
hypermethylation
testing
NGS
African American,
n = 55 (5.9%)
Asian, n = 17
(1.8%)
Other, n = 7
(0.7%)
Unknown/not
specified, n = 11
(1.2%)
Latham
2019
USA Retrospective
Cohort
Hospital Jan
2014-Jun
2017
525 Unclear Median
55–60 years
across all MSI
groups
NR for whole
sample
NR NR MSI and IHC NGS
Lu 2007 USA Prospective
cohort
Gynaecologic
oncology clinics
Jan 2000
end date
NR
100 Selected Mean 41.6 NR 12/100 (12%) 2
Colon 9 synchronous
ovarian 1 brain
21/100 (21%) LS
related cancer in at
least 1 first degree
relative
MSI, IHC and MLH1
promoter
hypermethylation
testing
Sequencing and
unclear further
testing for large
deletions
Median 43
(24–49) years
Mercado
2012
USA Retrospective
cohort study
Hospitals NR 129 Selected Median 63
(38–89) years
94 (73%)
Caucasian
34 (27%) CRC 115/129 (89%) CRC MSI, IHC DHPLC and
sequencing
1(1%) Hispanic 6 (5%) adenoma 48/129 (37%) EC
1 (1%) Asian 33(26%) other Lynch 67 (52%) Other LS
cancer2 (2%) other 37 (29%) Multiple LS
Ollikainen
2005
Finland Cohort
(retrospective
and
prospective)
Hospital 1986–1997 23 Selected Mean 62 years NR 2/23 (9%) breast
cancer
23/23 (100%) family
history of EC
MSI, IHC and MLH1
promoter
hypermethylation
testing
Sequencing and
MLPAMedian 61
(32–81) years
Ring 2016 USA Prospective
cohort
Hospital NR 381 Unselected
adult only
Mean 61 years
at diagnosis
Caucasian
n = 265 (70%)
NR NR for whole sample MSI, IHC and MLH1
promoter
hypermethylation
testing
NGS and MLPA
African–American
n = 34 (9%)
Hispanic n = 66
(17%)
Asian n = 14 (4%)
Native American
n = 2 (1%)
Ryan 2020 UK Prospective
cohort
Hospital 2 years 500 Unselected Median
65 years
White n = 405
(81%)
3/500 (0.6%) NR for whole sample IHC, MSI and MLH1
promoter
hypermethylation
testing
NGS and MLPA
Black n = 20 (4%)
Asian n = 55
(11%)
Chinese n = 10
(2%)
(continued on next page)
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Table 1 (continued)
Study
reference
Country Study design Study setting Time
period
Sample
size
included
Selected/
unselected
sample
Age Mean
Median (range
Ethnicity Previous /concurrent
cancers
Relatives Index test(s) Reference standard
tests(s)
Other n = 10
(2%)
Rubio 2016 Spain Retrospective
and
prospective
cohort
Hospital 3 years NR 103 Selected NR NR Colon, n = 20
(19.4%)
64/99 (65%) available
histories
MSI and IHC CSGE sequencing,
MLPA
Ovary, n = 14
(13.6%)
Skin, n = 4 (3.9%)
Salvador
2019
USA Retrospective
cohort study
Laboratory/hospital 2016–2018 237 Selected NR for EC
patients alone
NR for EC patients
alone
NR for EC sample
alone
NR for EC sample
alone
MSI, IHC and MLH1
promoter
hypermethylation
testing
NGS and MLPA
Tian 2019 China Propsective
cohort
Cancer centre Jan
2014-Jul
2017
198 Selected NR in whole
sample
Chinese 44/196 (22.4%)
multiple primary
tumour 20 CRC 6
ovarian
47/196 (24%) LS
related tumour in a
first degree relative
IHC Sequencing, NGS
and MLPA
Yoon 2008 Korea Prospective
cohort
Hospital Jan
1996-Dec
2004
113 Selected NR NR NR NGS and MLPA MSI, IHC and MLH1
promoter
methylation testing
Sequencing
CSGE = conformation sensitive gel electrophoresis, DGGE = denaturing gradient gel electrophoresis, DHPLC = Denaturing high performance liquid chromatography, EC = endometrial cancer, IHC = immunohistochemistry, MLPA = multiplex
ligation-dependent probe amplification, MSI = microsatellite instability, NGS = next-generation sequencing, NR = not reported.
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the reference standard domain, risk of bias was rated as unclear in all
seven studies [17–23]. The flow of patients through the study was
rated at high risk of bias in 57% of studies (4/7 studies) [17,18,20,21].
Three of the studies did not include all patients in their analysis
[18,20,21], and two studies did not give all patients the same reference
standard as sequencing was only conducted after positive testing with
conformation sensitive gel electrophoresis or denaturing gradient gel
electrophoresis [18,20]. The remaining three studies had a low risk
of bias [19,22,23]. Risk of bias due to the role of the sponsor was high
in two studies in which multiple authors were employed by compa-
nies who conducting testing for Lynch syndrome and funded the
studies [19,22].3.2.2. Partial test accuracy studies
Risk of bias was high in two or more domains for 67% of the studies
(4/6 studies) [24–27]. No study was at low risk of bias in all domains.
The areas where there were a high risk of bias were patient selection
(4/6 studies, 67%) [24–27], flow and timing (all studies) [16,24–28],
and the reference standard (1/5 studies, 20%) [27]. There were high ap-
plicability concerns in the patient selection domain in three studies
[24,25,27], with these studies narrowing their inclusion criteria by age
and personal/familial cancer history. No study had high applicability
concerns in the index test and reference standard domains.Fig. 4. Forest plots of comple
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3.3. Characteristics of included studies
Characteristics of the included studies are provided in Table 1. Of the
13 studies, seven studies provided complete test accuracy data [17–23],
and six studies provided partial test accuracy data [16,24–28]. Across
the 13 studies, there were approximately 3500 participants, ranging
from 23 [25] to 1043 [26] patients per study. Four studies took place in
European countries [16,17,20,25], three in Asian countries [18,21,24],
and six in the USA [19,22,23,26–28]. One study was conducted in an un-
selected population [16], and 12 studies in selected populations (i.e. par-
ticipants were limited to only those with particular characteristics, e.g.
under 50 years only, without a person/family history of cancer)
[17–28] . All studies within this review had a cohort design, 53.8% (6/
13) of studies were prospective cohorts [16,18,19,21,23,24,26], 23.1%
(3/13) were retrospective [22,27,28], and 23.1% (3/13) had both pro-
spective and retrospective elements [17,20,25].
3.4. Description of screening and diagnostic tests
Ninety-two per cent (12/13) of studies included both IHC and MSI
tests. One study used IHC only [21]. Sixty-two per cent (8/13) of studies
also included MLH1 promoter methylation testing [16,18,19,22–26].
In studies of IHC, seven studies tested all four IHC proteins (MLH1,
MSH2, MSH6 and PMS2) [16,18–22,27], and three studies tested three
proteins (MLH1, MSH2, MSH6) [23–25]. IHC cut-offs were not reportedte test accuracy studies.
Fig. 4 (continued).
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markers were used: BAT25, BAT26, D2S123, D5S346, and D17S250
[17,24–26]; BAT25, BAT26, BAT40, D2S123, D5S346, and D173250
[20,23]; and BAT-25, BAT-26, NR-21, NR-24, NR-27, and MONO-27
[16,18]. The panel of markers was not reported in four studies
[19,22,27,28]. The circumstances under which MLH1-PM testing was
conducted varied between studies. MLH1 promotermethylation testing
was conducted if tumours were categorised as MSI-H or had IHC loss
(MLH1 or MLH1/PMS2) in three studies [16,22,23], if tumours had IHC
MLH1 loss only in three studies [18,24,25], and in all participants in
one study [26]. In the remaining paper, the circumstances under
which MLH1-PM was conducted was not reported [19].
Cut-offs for index tests varied across studies. For IHC, index positive
was defined as complete absence of protein expression [19], any loss of
expression [16–18,23,27], or no evidence of protein expression [24]. IHC
cut-offs were not reported for the remaining five studies [20–22,24–28].
For MSI, index test positive was defined as MSI-H (≥ 2 instable markers)
in nine studies [16–18,22,23], and an MSI sensor score ≥ 10 in one study
[28]. For the remaining two studies, the cut-off was described as MSI-H
but the number ofmarkers indicating instabilitywas not reported [19,20].
A range of reference standards were employed: sequencing [24,27],
next-generation sequencing (NGS) [26,28], sequencing and multiplex
ligation-dependent problem amplification (MLPA) [16,17,19,20,22,25],
sequencing and NGS [18], sequencing, NGS, and MLPA [21], and se-
quencing with an unspecified method to detect large deletions [23].8
Three of the included studies used an additional reference standard
test prior to sequencing: conformation sensitive gel electrophoresis
[20], denaturing gel electrophoresis [17], and denaturing high perfor-
mance liquid chromatography [27].
3.5. Accuracy of screening tests
The methods, thresholds to determine positivity of index tests, and
the diagnostic tests varied between studies. Results were considered
positive when they exceeded the threshold as set in the individual
study. Forest plots of test accuracy metrics are given in Fig. 4 (complete
test accuracy) and Fig. 5 (partial test accuracy). Test failures are re-
ported in Supplement 6.
3.6. Complete test accuracy studies
3.6.1. Head-to-head studies
Four studies provided data that could be used to explore head-to-
head comparisons between IHC andMSI testing [17,18,20,23]. However,
the number of tumours assessed by IHC and MSI in each studies were
not identical. More IHC than MSI results were available in three studies
(102 vs. 83 [18], 99 vs. 95 [23], and 94 vs. 83 [20]), and more MSI than
IHC results were available in one study (57 vs. 51 [17]).
For IHC therewas combined total of 28 truepositives, 78 false positives,
235 true negatives, and 5 false negatives across the studies. For MSI there
Fig. 4 (continued).
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tives, and 8 false negatives in the studies. Median test accuracy estimates
were similar between the two tests. For sensitivity, estimates ranged
were 66.7–100% for IHC and 41.7–100% for MSI. For specificity, estimates
were 60.9–83.3% for IHC and 69.2–89.9% for MSI. For PPV, estimates
were 14.2–37.5% for IHC and 20–33.3% for MSI. For NPV, estimates were
95.2–100% for IHC and 88.8–100% for MSI. Within studies, confidence in-
tervals of IHC and MSI on each of the four test accuracy estimates over-
lapped, suggesting no statistically significant differences between the tests.
3.6.2. Immunohistochemistry alone
Data on IHC testing alone were available from five studies
[17,18,20,21,23]. There were 69 true positives, 193 false positive, 243
true negatives, and 6 false negatives. Test accuracy estimates ranged
from 66.7–100% for sensitivity, 6.5–83.3% for specificity, 14.2–37.5%
for PPV, and 88.9–100% for NPV. Excluding the study with highly selec-
tive inclusion criteria [21] narrowed the specificity range to 60.9–83.3%.
Test failures were reported for 0–1% of tumours for immunohistochem-
istry (1 out of 522 tumours).
3.6.3. Microsatellite instability-based testing alone
Data onMSI testing alone using two or moremarkers as a cut-off were
available from four studies [17,18,20,23]. There were 21 true positives, 57
false positive, 232 true negatives, and 8 false negatives. Test accuracy esti-
mates ranged from 41.7–100% for sensitivity, 69.2–89.9% for specificity,
20–33.3% for PPV, and 88.8–100% for NPV. No test failures were reported.9
Data on MSI testing using one or more markers as a cut-off were
available from one study [20]. There were 5 true positives, 17 false pos-
itives, 54 true negatives, and 7 false negatives. Sensitivity was 41.7%
(95% CI 16.5–71.4%), specificity was 76.1% (95% CI 64.2–85.1%), PPV
was 22.7% (95% CI 8.7–45.8%), and NPV was 88.5% (95% CI
77.2–94.9%). Using a cut-off of one or more stable marker (rather than
two or more) changed the status of one index test result from true neg-
ative to false positive. No test failures were reported.
3.6.4. Immunohistochemistry and microsatellite instability-based testing,
with MLH1 promoter methylation testing
Four studies provided test accuracy data for immunohistochemistry
andmicrosatellite instability-based testing [18,19,22,23]. Therewere 85
true positives, 290 false positives, 465 true negatives, and 4 false nega-
tives. Test accuracy estimates ranged from 90.5–100% for sensitivity,
2.6–92.3% for specificity, 18.3–56.3% for PPV, and 75–100% for NPV. Ex-
cluding the study with highly selective inclusion criteria [22] narrowed
the specificity range to 72.4–92.3%. Test failures were reported in one
study: 0.2% (1/567 tumours) for IHC [23]. No test failures were reported
for MSI or MLH1 promoter methylation testing.
3.7. Partial test accuracy studies
3.7.1. Immunohistochemistry alone
Two studies provided test accuracy data for IHC alone [16,27]. One
study assessed PPV for all proteins combined [16], and one study for
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proteins, there were 16 true positives, and 115 false positives from
500 women tested. PPV was 12.2% (95% CI 7.4–19.4%). In the study
that reported results by genes, PPV was lowest for MLH1 (75.0%) and
highest for PMS2 (81.8%) [27]. Test failures were reported in one
study [16], in which 13 (2.6%) tumours failed initial sample testing. Re-
peat testing was successful for all 13 samples.
3.7.2. Immunohistochemistry with MLH1 promoter methylation testing
One study provided test accuracy data for immunohistochemistry
with MLH1 promoter methylation testing [25]. There were 2 true posi-
tives, and 8 false positives from 23 women tested. PPV was 20% (95% CI
3.5–55.8%). No test failures were reported.
3.7.3. Microsatellite instability-based testing alone
Four studies provided test accuracy data forMSI [16,25,27,28]. There
were 33 true positives and 197 false positives from 1072women tested.
PPV estimates ranged from 5.9–75%. Test failures were reported in one
study [16], in which 8 (1.6%) tumours failed initial sample testing. Re-
peat testing was successful for all 8 samples.
3.7.4. Immunohistochemistry and microsatellite instability-based testing,
with MLH1 promoter methylation testing
Three studies provided test accuracy data for IHC, MSI and MLH1
promoter methylation testing [24–26]. There were 28 true positive10and 46 false positives from 1138 women tested. PPV estimates ranged
from 20 to 43.1%. Test failures were reported for 0–0.3% of tumours
for IHC (3/1179 tumours), none for MSI testing, and 0–3.7% (40/1180
tumours) for MLH1 promoter hypermethylation testing.4. Discussion
In this review, we evaluated the test accuracy of IHC and MSI (with
or without MLH1 promoter methylation testing) for Lynch syndrome
in women with endometrial cancer. In seven studies participants re-
ceived both the index test and the reference standard (complete test ac-
curacy studies), and in six studies only women who were positive on
the index tests were followed up with the reference standard (partial
test accuracy studies). In the complete test accuracy studies, sensitivity
ranged from 60.7–100% for IHC, 41.7–100% for MSI, and 90.5–100% for
IHC,MSI, andMLH1promotermethylation testing combined. Specificity
ranged from 6.5–83.3% for IHC, 69.2–89.9% for MSI, and 2.6–90.7% for
IHC,MSI, andMLH1 promotermethylation testing combined. Two stud-
ies reported very low specificity: 2.6% [22], and 6.5% [21]. In each of
these studies, the majority of participants had loss of MMR expression,
due to highly selective inclusion criteria. Removing these studies gave
specificity ranging from 60.9–83.3% for IHC, 69.2–89.9% for MSI, and
72.4–90.7% for IHC, MSI, and MLH1 promoter methylation testing
combined.
Fig. 5. Forest plots of partial test accuracy studies.
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ranged from 5.9–75% for MSI, 20% for IHCwithMLH1 promoter methyla-
tion testing, and 20–43.1% for studies that combined all three tests. There
is a range of possible explanations for the differences in test accuracy es-
timates, including whether the studies included selected- (e.g. limiting
participants by age, or prior/current cancer diagnosis) or unselected sam-
ples of participants, and variation in testing strategies (e.g. variable index
test thresholds, the number of proteins assessed for IHC, the panel of
markers used forMSI, and the reference standards used).We foundnoev-
idence of a difference in test accuracy between IHC and MSI in the four
studies that provided head-to-head data. The number of tumours
assessed by IHC and MSI in each studies were not identical. Typically,
thereweremore IHC tests conducted thanMSI tests. Therefore, the results
of the comparisons are subject to bias. Test failures were extremely low
for all three tests. This is possibly due to participants with insufficient tu-
mour tissue available for testing being excluded from the studies.
Caution is warranted in drawing strong conclusions on test accuracy
as the number of studies providing data on each test was small, as were
the overall sample sizes and number of cases of Lynch syndrome. Fur-
ther, the majority of studies were at high risk of bias in at least one do-
main, and there was considerable variability in study designs. Due to
these and other issues (e.g. a lack of information on ideal marker panels
for MSI-based strategies, and the impact of adding MLH1 promoter
hypermethylation testing), it is currently unclear whichmethod should
be selected for clinical practice.11In our review we separated papers into ‘complete’ test accuracy
studies (in which the reference standard was offered irrespective of
the result of the index test) and ‘partial’ test accuracy studies (in
which the reference standard was only offered to women who were
index test positive. The rationale being that although in some studies
index test negative cases are occasionally treated as true negatives to
allow sensitivity and specificity to be calculated, this can lead to overes-
timation of sensitivity. Our study supports this. Using the seven com-
plete test accuracy studies in our review, an assumption that the index
test results were correct would have led to overestimation of sensitivity
in 2/4 studies (50%) that assessed IHC alone (overestimating by
2.4–33.3%), 3/5 studies (60%) that assessed MSI alone (overestimating
by 20–58.5%), and 2/4 studies (50%) that assessed IHC, MSI, and MLH1
promoter methylation testing combined (overestimating by 3.8–9.5%).
Twoprevious systematic reviews have examined the test accuracy of
MSI [29], and IHC and MSI (with/without MLH1 promoter methylation
testing) to detect Lynch syndrome, albeit in people who have colorectal
cancer [11]. The authors reported sensitivity of 73.3–100% and specific-
ity of 12.5–100% for IHC [11], and sensitivity of 66.7–100% and specific-
ity of 61.1–92.5% [11,29]. These two reviews suggest that IHC and MSI
test have similar levels of test accuracy to detect Lynch syndrome in
people with colorectal and endometrial cancers. The low specificity re-
ported in two studies suggests refinement of the testing strategies
might be warranted before they are implemented in universal testing
programmes, due to the cost implications and psychological impact of
C. Stinton, H. Fraser, L. Al-Khudairy et al. Gynecologic Oncology xxx (xxxx) xxxtesting people who are ultimately determined not to have Lynch
syndrome.
The key strength of this review is thatwe followed the gold standard
methodology for conducting systematic reviews (which included inde-
pendent assessment at every stage) to identify evidence on test accu-
racy. Our review has a number of limitations. First, we excluded six
studies where we could not establish which reference standard was
used. In each case, we contact the paper's corresponding author. None
of the authors who replied was able to confirm how the Lynch syn-
dromediagnosis wasmade, as study samples had been sent to commer-
cial laboratories for assessment (in some cases more than one
laboratory). Follow up with the relevant laboratories did not lead to
confirmation of the tests used. Therefore, we cannot be certain these
studies did not meet our inclusion criteria. Second, in our protocol we
specified that Lynch syndrome had to be diagnosed by genetic confir-
mation of variants in the four MMR genes that are most commonly as-
sociated with Lynch syndrome (MLH1, MSH2, MSH6, and PMS2) using
diagnostic tests that we described in the best practice guidelines of
the Association for Clinical Genomic Sciences [30]. There is some evi-
dence that another gene (EPCAM) is responsible for 1–3% of cases of
Lynch syndrome [31]. Studies that were only concerned with the
EPCAMgene, or that used diagnostic test not specified in theAssociation
for Clinical Genomic Sciences guidelines would not have been captured
in our review. Third, we excluded grey literature and studies notwritten
in English. These studies might have provided additional information
that was relevant to our review. Fourth, we excluded studies where
fewer than 95% of participants whowere eligible for the reference stan-
dard received it. In complete test accuracy studies, this referred to 95%
of participants who had received the index test, and in the partial test
accuracy studies, this referred to 95% of participants who were positive
on the index test.We employed this approach tominimise biases in the
test accuracy estimates, as systematic reasons why participants de-
clined/were not offered the reference standard (e.g. people who are at
higher/lower risk of a disease are systematically not being followed
up) can affect test accuracy estimates. However, the decision to set the
threshold at 95% was pragmatic.
5. Conclusions
Our review suggests that the sensitivity of the index testswere gener-
ally high. Most studies reported much lower levels of specificity, which
might be problematic for universal screening programmes in terms of
the costs and psychological implications of conducting genetic testing
on women who do not have Lynch syndrome. We found no evidence
that test accuracy differs between IHC and MSI based strategies. The evi-
dence base is currently small and at high risk of bias. Additional studies
that follow up participants who are index test negative with reference
standards would provide greater clarify on the accuracy of IHC and MSI
to detect Lynch syndrome in women who have endometrial cancer.
Definition of test accuracy termsF
F
N
P
S
S
T
alse negative The index test is negative but the person does has the disease
alse positive The index test is positive but the person does not have the
disease
egative
predictive valueThe probability that a person with a negative index test result
truly does not have the diseaseositive
predictive valueThe probability that a person with a positive index test result
truly does have the diseaseensitivity The ability of an index test to correctly identify people with
the diseasepecificity The ability of an index test to correctly identify people
without the diseaserue negative The index test if negative and the person does not have the
diseaserue positive The index test is positive and the person does have the diseaseT12Declarations
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